Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | TLR2 | O60603 | 2/20 | 0.39 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.39 |
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.39 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.39 |
| ▸ | GLP1R | P43220 | 8/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16093009 | 0.78 | GLP1R (0.38) | CYP1A2CYP3A4CYP2C19TLR2NOD1 | |
| SCHEMBL16093019 | 0.76 | GLP1R (0.41) | TLR2NOD1GLP1R | |
| SCHEMBL29475665 | 0.75 | CA1 (0.42) | TLR2NOD1 | |
| SCHEMBL23743175 | 0.75 | KDM4E (0.40) | NOD1GLP1R | |
| SCHEMBL23743173 | 0.75 | KDM4E (0.40) | NOD1GLP1R | |
| SCHEMBL16093004 | 0.75 | GLP1R (0.37) | TLR2NOD1GLP1R | |
| SCHEMBL19069621 | 0.74 | GLP1R (0.42) | TLR2NOD1GLP1R | |
| SCHEMBL15871323 | 0.73 | GLP1R (0.54) | NOD1GLP1R | |
| SCHEMBL31092066 | 0.73 | NOD1 (0.64) | TLR2PLA2G2CNOD1 | |
| SCHEMBL7520670 | 0.73 | NOD1 (0.64) | TLR2PLA2G2CNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841249-B2 | Growth hormones with prolonged in-vivo efficacy | NOVO NORDISK A/S (DK) | 2014-09-23 | — | — | US | disclosed |
| US-8841249-B2 | Growth hormones with prolonged in-vivo efficacy | NOVO NORDISK A/S (DK) | 2014-09-23 | — | — | US | disclosed |